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〔目的〕 
T cell receptor (TCR)-T cell therapy is drawing attention as a promising next-generation 
immunological cancer therapy. To achieve a significant therapeutic effect in TCR-T cell 
therapy, highly functional tumor-specific TCRs are prerequisite. Tumor-infiltrating 
lymphocytes (TILs) are a potent source for obtaining tumor-reactive TCRs. Although 
comprehensive methods to analyze the TCR repertoire in TILs have been reported, 
tumor-reactivity of TCRs in TILs has not been comprehensively analyzed. The function of 
only five to ten TCR clones from fifty to thousands of obtained TCRs have been 
conventionally analyzed to obtain tumor-reactive TCRs. This is because examination of dual 
TCRα- or β-expression in a single T cell and their functional combination, preparation of 
TCR-expression vectors and their assessment of DNA sequences is extremely complicated 
and laborious. The aim of this study is to develop the method for comprehensive analysis of 
the tumor-reactivity of TCRs derived from TILs. 
 〔方法〕 
We developed a novel, efficient, and comprehensive evaluation system for TCR-function 
and designated it c-FIT (comprehensive functional investigation of TCRs). In the c-FIT 
system, we prepare retroviral TCR-expression vectors without cloning and sequencing. In 
detail, we insert cDNAs of TCRβ and α into retrovirus vector using homologous 
recombination and connect TCRβ, TCRα fragments, and the blasticidin S-resistant gene 
(Bsr) with a nucleotide sequence encoding self-cleaving 2A peptides. We named the vector 
TCR-2A-Bsr. The resultant plasmids contained not only functional TCR-expression vectors 
but also unfunctional ones. We transfect the mixture of functional and unfunctional 
TCR-expression vectors into a BW5147.3 reporter T cell line, which exhibits strong 
sensitivity to stimuli from antigen presenting tumor cells. We then culture the transfectants 
in the presence of blasticidin S to enrich the transfectants with functional TCR-expression 
vectors, in which TCRβ and TCRα fragments are connected to Bsr in frame. We then 
 
coculture TCR-transduced BW5147.3 reporter cells with target cells and assess the reactivity 
of TCRs to the target cells by analyzing IL-2-secretion with ELISA. When analyzing the 
cytotoxicity-inducibility of TCRs, we transfect TCR-expression vector into peripheral blood 
T cells and coculture them with target cells expressing luciferase, whose activity corresponds 
to live cell number. 
〔成績〕 
To assess the c-FIT system using clinical samples, we single cell-sorted PD-1+ CD137+ 
CD8+ TILs of two breast cancer patients, analyzed the TCR repertoire and amplified the 
clones of TCRβ and TCRα cDNA. We then prepared the bulk TCR-2A-Bsr vector for each 
TIL clone, retrovirally transferred the vectors into BW5147.3 reporter cells expressing 
human CD8αβ and cultured them in the presence of blasticidin S. As target cells, we used 
breast cancer cell lines (MCF7) in which the patient’s HLA molecules were exogenously 
expressed. We analyzed 70 TCRs obtained from CD8+ TILs of two breast cancer patients 
and found 23 TCRs that reacted to a breast tumor cell line. Surprisingly, two TCRs were 
patient’s HLA class I-restricted and conventional TCRs, while the remaining 21 TCRs were 
non-HLA-restricted unconventional TCRs. Representative two obtained TCRs responded 
and killed MCF7 cells when expressed on human peripheral blood T cells. 
 〔総括〕 
We established a novel method, c-FIT, that is suitable for comprehensive assays for the 
function of TCRs. c-FIT does not require cloning and verification of TCR-expression vectors 
or the troublesome dual expression of TCRα or β in a single T cell. Furthermore, the c-FIT 
protocol uses BW5147.3 reporter cells, the most sensitive reporter mouse T cell line, for the 
functional assay. c-FIT system enables us to analyze up to 90 TCRs for their reactivity to 
tumor cells by a single assay within a month. c-FIT can be applied for monitoring multiple 
conventional and unconventional antigen-specific killer T cells in TILs, leading to the 
development of new designs for more effective T-cell-based immunotherapies. 
 


